Search

Your search keyword '"Michael D. Mix"' showing total 3 results
Start Over Author "Michael D. Mix" Search Limiters Available in Library Collection
3 results on '"Michael D. Mix"'

1. Imbalanced specialty representation of USMLE and NBME test writers

Author

Mary T. Mahoney, Lauren C. Linkowski, Michael D. Mix, Roger Wong, Austin J. Sim, Sarah E. Hoffe, and Karna T. Sura

Subjects
Undergraduate Medical Education, United States medical licensing Exam® (USMLE®), Medical Specialities, Standardized medical examinations, Special aspects of education, LC8-6691, Medicine
Abstract

Abstract Purpose The United States Medical Licensing Examination (USMLE) is an examination series required for allopathic physician licensure in the United States (US). USMLE content is created and maintained by the National Board of Medical Examinations (NBME). The specialty composition of the USMLE and NBME taskforce members involved in the creation of examination content is currently unknown. Methods Using the 2021 USMLE and 2021 NBME Committees and Task Forces documents, we determined each member’s board-certified primary specialty and involvement in test material development committees who we dubbed “test writers”. Total active physicians by primary specialty were recorded from the 2020 Physician Specialty Data Report published by the Association of American Medical Colleges (AAMC). Descriptive statistics and chi-square analysis were used to analyze the cohorts. Results The USMLE and NBME test writer primary specialty composition was found to be significantly different compared to the US active physician population (USMLE χ2[32] = 172, p

Published
2024
Full Text
View/download PDF

2. Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research

Author

Parth J. Sampat, Alyssa Cortese, Alexandra Goodman, Ghanshyam H. Ghelani, Michael D. Mix, Stephen Graziano, and Alina Basnet

Subjects
brain metastases, non-small cell lung cancer, non-small cell adenocarcinoma, lung cancer, squamous cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Lung cancer is the second most common type of cancer and is the leading cause of cancer-related deaths in the United States. Approximately 10-40% of patients with solid tumors develop brain metastases, with non-small cell lung cancer accounting for approximately 50% of all cases of patients with brain metastases. Many management options are available which can include surgery, radiation, and systemic therapy. A variety of factors go into the selection of management of brain metastases. In this review, we will focus on the treatment strategies and optimizing the management of brain metastases in patients with non-small cell lung cancer.

Published
2024
Full Text
View/download PDF

3. Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

Author

Jared Deck, Marissa Hartley, Mohammad Akhter, Dongliang Wang, Jeffrey A Bogart, and Michael D Mix

Subjects
Oncology, Targets and Therapy [Lung Cancer]
Abstract

Jared Deck,1 Marissa Hartley,1 Mohammad Akhter,1 Dongliang Wang,2 Jeffrey A Bogart,1 Michael D Mix1 1Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 2Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USACorrespondence: Jared Deck, Department of Radiation Oncology, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13202, USA, Tel +1 (315)-464-5276, Email deckj@upstate.eduBackground: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with hematologic metrics and might predict clinical outcomes.Materials and Methods: Patients with stage III NSCLC treated at a single institution between 2011 and 2018 were retrospectively reviewed. Pre-treatment gross tumor volume (GTV) was recorded then reassessed at 1– 4 months post-CRT. Complete blood counts before, during and after treatment were recorded. Systemic immune-inflammation index (SII) was defined as neutrophil × platelet/lymphocyte. Overall survival (OS) and progression free survival (PFS) were calculated using Kaplan-Meier estimates, and compared with Wilcoxon tests. A multivariate analysis of hematologic factors impacting restricted mean survival was then performed using pseudovalue regression, accounting for other baseline factors.Results: 106 patients were included. After median follow-up of 24 months, median PFS and OS were 16 and 40 months, respectively. Within the multivariate model, baseline SII was associated with OS (p = 0.046) but not PFS (p = 0.09), and baseline ALC correlated with both PFS and OS (p = 0.03 and p = 0.02, respectively). Nadir ALC, nadir SII, and recovery SII were not associated with PFS or OS.Conclusion: In this cohort of patients with stage III NSCLC, baseline hematologic factors were associated with clinical outcomes including baseline ALC, baseline SII and recovery ALC. Disease response was not well correlated with hematologic factors or clinical outcomes.Keywords: lymphopenia, myelosuppression, chemoradiation, tumor response

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results